IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
IDEAYA Biosciences (NASDAQ: IDYA) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:45 PM PT (6:45 PM ET).
Presentation by Yujiro S. Hata, Chief Executive Officer, followed by an analyst-hosted Q&A with Anupam Rama, Managing Director, J.P. Morgan. A live audio webcast will be available via the company's Investors/Events webpage, with a replay accessible for 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, IDYA gained 3.22%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: DNLI -2.34%, BLTE -0.46% versus GLPG +0.52%, FOLD +0.18%, TVTX +1.05%, suggesting stock-specific factors rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Pivotal trial enrollment | Positive | -0.2% | Completed enrollment of 435 patients in OptimUM-02 Phase 2/3 trial. |
| Dec 10 | IND submission | Positive | -1.3% | Submitted IND for IDE574 targeting Phase 1 trial initiation. |
| Dec 04 | IND clearance | Positive | +4.7% | Received FDA IND clearance for IDE034 ADC from Biocytogen license. |
| Dec 01 | IND clearance detail | Positive | -3.7% | Detailed IDE034 IND clearance and target tumor types, plus co-expression data. |
| Nov 28 | Equity inducement grant | Neutral | -0.7% | Granted 17,600 stock options to a new hire under inducement plan. |
Recent news has mostly been positive clinical or pipeline progress, yet price reactions often skew negative or muted, with only one clearly positive move, indicating a tendency for the stock to underreact or sell off on good news.
Over the last few months, IDEAYA has reported several notable developments. These include full enrollment of 435 patients in the pivotal OptimUM-02 Phase 2/3 trial and an IND submission for IDE574 targeting a Phase 1 start in Q1 2026. The company also secured FDA IND clearance for IDE034, a bispecific B7H3/PTK7 TOP1 ADC, with Phase 1 enrollment planned in Q1 2026. An inducement grant of 17,600 options was issued under the 2023 Inducement Plan. Against this backdrop of expanding clinical activity, today’s conference participation fits as continued investor outreach rather than a new catalyst.
Market Pulse Summary
This announcement highlights IDEAYA’s participation in a major investor-focused event, the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. It signals continued engagement with the investment community rather than a new clinical or financial catalyst. In light of recent milestones, including pivotal trial enrollment and multiple IND clearances, investors may focus on any strategic updates shared during the 3:45 PM PT presentation and subsequent Q&A, as well as follow-up disclosures that quantify clinical or financial impacts.
Jargon Translator
AI-generated analysis. Not financial advice.
44th Annual J.P. Morgan Healthcare Conference
Monday, January 12th, 2026, at 3:45 PM PT (6:45 PM ET)
- Presentation by Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences, followed by analyst-hosted Q&A with Anupam Rama, Managing Director, US SMID Biotechnology Equity Research, J.P. Morgan
A live audio webcast of the presentation and Q&A session will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcast will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-participation-at-the-44th-annual-jp-morgan-healthcare-conference-302651807.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
When will IDEAYA (IDYA) present at the J.P. Morgan Healthcare Conference?
Who will present for IDEAYA (IDYA) at the January 12, 2026 session?
How can investors access IDEAYA's (IDYA) live webcast on January 12, 2026?
Will IDEAYA's (IDYA) webcast be available after the live presentation?
Will there be a Q&A during IDEAYA's (IDYA) J.P. Morgan presentation?
What is the ticker symbol for IDEAYA Biosciences referenced for investor searches?
